Coated Recombinant Target Protein Helps Explore IL-1RAP CAR T-cell Functionality in Vitro

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2022 Dec 1

PMID 36456721

Authors

Mathieu Neto Da Rocha

Melanie Guiot

Clementine Nicod

Rim Trad

Lucie Bouquet

Rafik Haderbache

Walid Warda

Pierre-Emmanuel Baurand

Chloe Jouanneau

Philippe Dulieu

Marina Deschamps

Christophe Ferrand

Affiliations

Soon will be listed here.

Citing Articles

A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.

Maali A, Noei A, Feghhi-Najafabadi S, Sharifzadeh Z Iran Biomed J. 2025; 28(5 & 6):221-34.

PMID: 39891450 PMC: 11829154. DOI: 10.61186/ibj.4444.

Artificial Targets: a versatile cell-free platform to characterize CAR T cell function .

Wang X, Tokarew N, Borgelt N, Siemer R, Melo C, Langer C Front Immunol. 2024; 15:1254162.

PMID: 38433827 PMC: 10906080. DOI: 10.3389/fimmu.2024.1254162.

IL-1 Family Members in Bone Sarcomas.

Landuzzi L, Ruzzi F, Pellegrini E, Lollini P, Scotlandi K, Manara M Cells. 2024; 13(3.

PMID: 38334625 PMC: 10854900. DOI: 10.3390/cells13030233.

Broadening the horizon: potential applications of CAR-T cells beyond current indications.

Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A Front Immunol. 2023; 14:1285406.

PMID: 38090582 PMC: 10711079. DOI: 10.3389/fimmu.2023.1285406.

RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.

Bouquet L, Bole-Richard E, Warda W, Neto Da Rocha M, Trad R, Nicod C Gene Ther. 2023; 30(9):706-713.

PMID: 37173386 PMC: 10506905. DOI: 10.1038/s41434-023-00404-2.

References

Lipsitz Y, Timmins N, Zandstra P . Quality cell therapy manufacturing by design. Nat Biotechnol. 2016; 34(4):393-400. DOI: 10.1038/nbt.3525. View

Olivo Pimentel V, Yaromina A, Marcus D, Dubois L, Lambin P . A novel co-culture assay to assess anti-tumor CD8 T cell cytotoxicity via luminescence and multicolor flow cytometry. J Immunol Methods. 2020; 487:112899. DOI: 10.1016/j.jim.2020.112899. View

Kiesgen S, Messinger J, Chintala N, Tano Z, Adusumilli P . Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat Protoc. 2021; 16(3):1331-1342. PMC: 8064272. DOI: 10.1038/s41596-020-00467-0. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Davenport A, Cross R, Watson K, Liao Y, Shi W, Prince H . Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci U S A. 2018; 115(9):E2068-E2076. PMC: 5834689. DOI: 10.1073/pnas.1716266115. View

Aktas E, Kucuksezer U, Bilgic S, Erten G, Deniz G . Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2008; 254(2):149-54. DOI: 10.1016/j.cellimm.2008.08.007. View

Warda W, Neto Da Rocha M, Trad R, Haderbache R, Salma Y, Bouquet L . Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther. 2021; 28(12):1365-1375. PMC: 8636256. DOI: 10.1038/s41417-020-00284-3. View

Padhan K, Varma R . Immunological synapse: a multi-protein signalling cellular apparatus for controlling gene expression. Immunology. 2010; 129(3):322-8. PMC: 2826677. DOI: 10.1111/j.1365-2567.2009.03241.x. View

Lorenzo-Herrero S, Sordo-Bahamonde C, Gonzalez S, Lopez-Soto A . CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity. Methods Mol Biol. 2018; 1884:119-130. DOI: 10.1007/978-1-4939-8885-3_7. View

10.

Alter G, Malenfant J, Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294(1-2):15-22. DOI: 10.1016/j.jim.2004.08.008. View

11.

Garcia E, Ismail S . Spatiotemporal Regulation of Signaling: Focus on T Cell Activation and the Immunological Synapse. Int J Mol Sci. 2020; 21(9). PMC: 7247333. DOI: 10.3390/ijms21093283. View

12.

Watanabe K, Kuramitsu S, Posey Jr A, June C . Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. Front Immunol. 2018; 9:2486. PMC: 6212550. DOI: 10.3389/fimmu.2018.02486. View

13.

Neal L, Bailey S, Wyatt M, Bowers J, Majchrzak K, Nelson M . The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. J Immunol Res Ther. 2017; 2(1):68-79. PMC: 5560309. View

14.

Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B . KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-1342. PMC: 7731441. DOI: 10.1056/NEJMoa1914347. View

15.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

16.

Xhangolli I, Dura B, Lee G, Kim D, Xiao Y, Fan R . Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T1/T2 Response Independent of Differentiation. Genomics Proteomics Bioinformatics. 2019; 17(2):129-139. PMC: 6620429. DOI: 10.1016/j.gpb.2019.03.002. View

17.

Dirar Q, Russell T, Liu L, Ahn S, Dotti G, Aravamudhan S . Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces. PLoS One. 2020; 15(9):e0238819. PMC: 7518621. DOI: 10.1371/journal.pone.0238819. View

18.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z . CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. Cancer Res. 2018; 79(3):663-675. DOI: 10.1158/0008-5472.CAN-18-1078. View

19.

Ukrainskaya V, Rubtsov Y, Pershin D, Podoplelova N, Terekhov S, Yaroshevich I . Antigen-Specific Stimulation and Expansion of CAR-T Cells Using Membrane Vesicles as Target Cell Surrogates. Small. 2021; 17(45):e2102643. DOI: 10.1002/smll.202102643. View

20.

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View